However, based on the immune-activating TME effects induced by the IL-12–tethered T cells, coupled with negative regulatory feedback from also up-regulating PD-L1 expression on activated myeloid lineage cells in the tumor, we reasoned that checkpoint blockade may further enhance tumor immune activity and antitumor efficacy. The gene discussed is CD274; the disease is neoplasm.